Track simple signals of benefit: fewer snacks, smaller portions, consistent bowel habits, and a small downward trend on the scale over 8-12 weeks
This results in more consistent and efficient absorption, even at lower doses
L-carnitine and ALCAR homeostasis are maintained by absorption from diet, a modest rate of synthesis, very efficient renal re-absorption and probably renal tubular secretion
Includes everything in GLP-2 plus maximum therapeutic dose, weekly medical support and monitoring, advanced metabolic optimization, and personalized wellness integration
Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
